{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:38:35Z","timestamp":1792175915558,"version":"4.4.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This study aimed to assess the efficacy and safety of Tongxinluo capsule (TXLC) in combination with conventional therapies for treating stable angina pectoris (SAP) through a comprehensive meta-analysis and systematic review.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a systematic search of the China National Knowledge Infrastructure, Wanfang, VIP, PubMed, Embase, and CENTRAL databases for randomized controlled trials investigating the use of TXLC as adjuvant therapy for SAP published up to June 2023. The Cochrane Handbook was used to evaluate the risk of bias. Meta-analysis was performed using Review Manager 5.4.1, and publication bias was assessed using Begg test and Egger test in the Stata SE 12.0 software. GRADEpro was used to assess the quality of the evidence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This meta-analysis included 26 randomized controlled trials with a total of 2352 patients. TXLC co-administration demonstrated significant reduction in angina attack frequency (mean difference (MD) \u22120.91, 95% confidence interval (CI) \u22120.97 to \u22120.84, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001) and duration (MD \u22121.71, 95% CI \u22122.24 to \u22121.19, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001), decreased use of nitroglycerin tablets (MD \u22126.28, 95% CI \u22127.16 to \u22125.41, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001), lowered C-reactive protein (MD \u22121.19, 95% CI \u22121.35 to \u22121.03, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001) and low-density lipoprotein cholesterol levels (MD \u22120.68, 95% CI \u22120.86 to \u22120.51, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.00001). TXLC co-administration did not increase gastrointestinal reactions (RR 1.17, 95% CI 0.38 to 3.57, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.78). The Begg test and Egger test results indicated no publication bias. The evidence quality was rated as very low for frequency of angina attack, duration of angina attack, and nitroglycerin usage, and low for C-reactive protein, low-density lipoprotein cholesterol levels, and gastrointestinal reaction events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This meta-analysis supports TXLC as a beneficial adjunct treatment for SAP.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035405","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:10:40Z","timestamp":1697231440000},"page":"e35405","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Tongxinluo capsule in combination with conventional therapies for stable angina pectoris: A meta-analysis and systematic review"],"prefix":"10.1097","volume":"102","author":[{"given":"Ruli","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-5099","authenticated-orcid":false,"given":"Qian","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixun","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJMc1605394","article-title":"Chronic stable angina.","volume":"375","author":"Wanitschek","year":"2016","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial invasive or conservative strategy for stable coronary disease.","volume":"382","author":"Maron","year":"2020","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2021.1527","article-title":"Diagnosis and management of stable angina: a review.","volume":"325","author":"Joshi","year":"2021","journal-title":"JAMA"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"805266","DOI":"10.3389\/fphar.2022.805266","article-title":"Tongxinluo may alleviate inflammation and improve the stability of atherosclerotic plaques by changing the intestinal flora.","volume":"13","author":"Qi","year":"2022","journal-title":"Front Pharmacol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"108767","DOI":"10.1016\/j.biopha.2019.108767","article-title":"Tongxinluo may stabilize atherosclerotic plaque via multiple mechanisms scanning by genechip.","volume":"113","author":"Ma","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FJC.0000000000000226","article-title":"Tongxinluo (TXL), a Traditional Chinese Medicinal Compound, improves endothelial function after chronic hypoxia both in vivo and in vitro.","volume":"65","author":"Zheng","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"R8-20250504","first-page":"2858","article-title":"No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: a randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT Trial).","volume":"123","author":"Zhang","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R10-20250504","first-page":"81","article-title":"Observation of the therapeutic effects of Tongxinluo on effort angina with hyperlipidemia.","volume":"20","author":"Xiaohong","year":"2004","journal-title":"J Guangdong Pharmac Univ"},{"key":"R11-20250504","first-page":"382","article-title":"Observation of the therapeutic effects of Tongxinluo on stable angina.","volume":"16","author":"Miao","year":"2006","journal-title":"Shenzhen J Int Trad Chin Western Med"},{"key":"R12-20250504","first-page":"36","article-title":"Observation of the therapeutic effects of Tongxinluo capsules in adjunctive treatment of stable coronary artery disease patients.","volume":"2","author":"Miaolian","year":"2009","journal-title":"Chin J Clin Rational Drug Use"},{"key":"R13-20250504","first-page":"297","article-title":"Clinical study of the effects of Tongxinluo capsules on stable angina and its inflammatory markers.","volume":"34","author":"Ailian","year":"2014","journal-title":"Health Res"},{"key":"R14-20250504","first-page":"172","article-title":"Effect and influence on lipid profiles of metoprolol combined with Tongxinluo capsules in patients with coronary heart disease angina.","volume":"39","author":"Xinping","year":"2021","journal-title":"Chin Health Care"},{"key":"R15-20250504","first-page":"297","article-title":"Clinical observation of Tongxinluo capsules in the treatment of stable angina in coronary heart disease.","volume":"16","author":"Hairu","year":"2007","journal-title":"Mod J Int Trad Chin Western Med"},{"key":"R16-20250504","first-page":"54","article-title":"Effect of Tongxinluo capsules for treating elderly patients with angina pectoris of coronary heart disease and its effect on the levels of inflammatory factors.","volume":"27","author":"Jun","year":"2018","journal-title":"China Pharm"},{"key":"R17-20250504","first-page":"385","article-title":"Effect of Tongxinluo capsules on blood lipid levels and clinical efficacy analysis in elderly patients with coronary heart disease angina.","volume":"33","author":"Dong","year":"2020","journal-title":"J Med Theory Pract"},{"key":"R18-20250504","first-page":"27","article-title":"To analyze the clinical effect of Tongxinluo capsule combined with routine treatment on stable angina pectoris of coronary heart disease.","volume":"3","author":"Jinjun","year":"2017","journal-title":"Smart Healthcare"},{"key":"R19-20250504","first-page":"401","article-title":"Treatment of 39 cases of chronic stable anguina pectoris with Tongxinluo capsule.","volume":"23","author":"Yaqing","year":"2007","journal-title":"J Nanjing Univ Trad Chin Med"},{"key":"R20-20250504","first-page":"62","article-title":"Treatment of chronic stable angina with Tongxinluo capsules: a study of 39 cases.","volume":"13","author":"Jia","year":"2020","journal-title":"Chin J Clin Rational Drug Use"},{"key":"R21-20250504","first-page":"2815","article-title":"Effects of Tongxinluo capsules on myocardial fibrosis and cardiac function in patients with coronary heart disease stable angina.","volume":"41","author":"Yinchuan","year":"2020","journal-title":"J Qiqihar Med Univ"},{"key":"R22-20250504","first-page":"79","article-title":"Clinical efficacy analysis of the combined treatment of isosorbide dinitrate and Tongxinluo capsules in coronary heart disease angina.","volume":"477","author":"Hexi","year":"2021","journal-title":"China Health Vision"},{"key":"R23-20250504","first-page":"2605","article-title":"Effects of Tongxinluo capsuless combined with betaloc on cardiac function in patients with stable angina pectoris of coronary heart disease.","volume":"16","author":"Fang","year":"2021","journal-title":"World Chin Med"},{"key":"R24-20250504","first-page":"36","article-title":"Effect of Tongxinluo capsule combined with betaloc on blood lipid level and cardiac function in patients with stable angina pectoris.","volume":"3","author":"Jicong","year":"2022","journal-title":"Reflexol Rehabil Med"},{"key":"R25-20250504","first-page":"2690","article-title":"Observation of the therapeutic efficacy of Tongxinluo in treating elderly patients with coronary heart disease angina.","volume":"16","author":"Suling","year":"2007","journal-title":"Mod J Int Trad Chin Western Med"},{"key":"R26-20250504","first-page":"23","article-title":"The therapeutic effect on left ventricle diastolic function of the senile stable angina pectoris by using Tong xin luo.","volume":"40","author":"Huiling","year":"2009","journal-title":"Guangzhou Med J"},{"key":"R27-20250504","first-page":"2780","article-title":"Clinical observation of Tongxinluo capsules in the treatment of coronary artery atherosclerotic heart disease angina: a study of 90 cases.","volume":"31","author":"Lianxiang","year":"2009","journal-title":"Hebei Med J"},{"key":"R28-20250504","first-page":"34","article-title":"Clinical observation of Tongxinluo capsules in the treatment of coronary artery atherosclerotic heart disease angina: a study of 90 cases.","volume":"25","author":"Lei","year":"2015","journal-title":"J Shanxi Health Vocational College"},{"key":"R29-20250504","first-page":"113","article-title":"Tongxinluo Jiaonang in treatment of 42 cases of coronary heart disease and angina pectoris.","volume":"42","author":"Xiaohui","year":"2015","journal-title":"Liaoning J Trad Chin Med"},{"key":"R30-20250504","first-page":"1482","article-title":"Clinical observation on 24 cases of chronic obstructive pulmonary disease of stationary phase combined with stable angina pectoris with Qi deficiency-blood stasis-phlegm blockade syndrome: simultaneous intervention for heart and lung.","volume":"58","author":"Yujin","year":"2017","journal-title":"J Tradit Chin Med"},{"key":"R31-20250504","first-page":"1693","article-title":"Evaluation of the effect of Tongxinluo capsules combined with conventional treatment on coronary heart disease angina with elevated homocysteine levels.","volume":"33","author":"Weichong","year":"2020","journal-title":"J Math Med"},{"key":"R32-20250504","first-page":"134","article-title":"Clinical observation on integrated traditional Chinese Medicine and Western Medicine in the treatment of angina pectoris of coronary heart disease.","volume":"19","author":"Yuanqin","year":"2021","journal-title":"Chin Med Mod Distance Educ China"},{"key":"R33-20250504","first-page":"518","article-title":"Clinical observation of Tongxinluo in the treatment of stable effort angina.","volume":"18","author":"Hongyu","year":"2005","journal-title":"J Handan Med College"},{"key":"R34-20250504","first-page":"1572","article-title":"Clinical observation of Tongxinluo capsules combined with rosuvastatin calcium in the treatment of angina: a study of 56 cases.","volume":"29","author":"Jinzhu","year":"2018","journal-title":"Mod Diagn Treat"},{"key":"R35-20250504","first-page":"3076","article-title":"Clinical observation of Tongxinluo capsules combined with rosuvastatin calcium in the treatment of angina: a study of 56 cases.","volume":"32","author":"Bing","year":"2019","journal-title":"J Med Theory Pract"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-019-0233-y","article-title":"The myth of \u201cstable\u201d coronary artery disease.","volume":"17","author":"Fox","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bmj.38603.656076.63","article-title":"Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients.","volume":"331","author":"Clayton","year":"2005","journal-title":"BMJ (Clinical Research ed)"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bmj.38603.656076.63","article-title":"Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients.","volume":"331","author":"Clayton","year":"2005","journal-title":"BMJ"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: principles and procedures.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research ed)"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial.","volume":"7","author":"Richardson","year":"2019","journal-title":"Clin Epidemiol Global Health"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14740338.5.5.667","article-title":"Side effects of using nitrates to treat angina.","volume":"5","author":"Thadani","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"R42-20250504","first-page":"11","article-title":"Bioactivation of organic nitrates and the mechanism of nitrate tolerance.","volume":"16","author":"Klemenska","year":"2009","journal-title":"Cardiol J"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fimmu.2018.00430","article-title":"C-Reactive protein in atherothrombosis and angiogenesis.","volume":"9","author":"Badimon","year":"2018","journal-title":"Front Immunol"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1373\/clinchem.2015.243923","article-title":"Interplay between CRP, atherogenic LDL, and LOX-1 and its potential role in the pathogenesis of atherosclerosis.","volume":"62","author":"Stancel","year":"2016","journal-title":"Clin Chem"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41598-019-41118-z","article-title":"Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): a multicenter randomized double-blind parallel-group placebo-controlled study.","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci Rep"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"115033","DOI":"10.1016\/j.jep.2022.115033","article-title":"Tongxinluo capsule as supplementation and cardiovascular endpoint events in patients with coronary heart disease: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials.","volume":"289","author":"Lv","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm11112991","article-title":"Efficacy and safety of different courses of Tongxinluo capsule as adjuvant therapy for coronary heart disease after percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.","volume":"11","author":"Hui","year":"2022","journal-title":"J Clin Med"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"7985459","DOI":"10.1155\/2023\/7985459","article-title":"To investigate the clinical efficacy and potential mechanism of Tongxinluo capsules in preventing coronary restenosis based on meta-analysis and network pharmacology analysis.","volume":"2023","author":"Wei","year":"2023","journal-title":"Evid Based Complem Altern Med"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"742978","DOI":"10.3389\/fphar.2021.742978","article-title":"Efficacy and safety of Tongxinluo capsule as adjunctive treatment for unstable angina pectoris: a systematic review and meta-analysis of randomized controlled trials.","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:14:16Z","timestamp":1746324856000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":51,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035405","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}